Multiple Endocrine Neoplasia (MEN1, MEN2A, and MEN2B) is a family of rare, autosomal dominant hereditary syndromes that cause tumors to develop in the endocrine glands — most often the thyroid, parathyroid, pituitary, pancreas, and adrenal glands. Because the mutations are inherited, carriers are typically identified young and begin lifelong tumor screening as early as age 5, long before any symptoms appear. That early start might suggest a childhood overshadowed by illness — but the newest research suggests the picture is more specific and more surprising than that.
What the research shows about quality of life
A 2026 nationwide Dutch study in the Journal of Clinical Endocrinology & Metabolism compared 77 children and adolescents (ages 5-18) with genetically confirmed MEN1, MEN2A, or MEN2B to 26 of their siblings without the condition and to healthy national norms, using the Pediatric Quality of Life Inventory (PedsQL). Children with MEN1 and MEN2A reported health-related quality of life comparable to their siblings and to the general population. Only children with MEN2B showed significantly lower physical quality of life. What mattered most was not carrier status itself, but whether a child had already developed clinical manifestations of the condition: children with MEN1 or MEN2B who had visible disease-related symptoms scored significantly lower on physical, social, and school functioning than carriers who had not yet developed symptoms.
Everyday challenges
- Starting surveillance before you can remember a time without it For many carriers, tumor screening begins as early as age 5, meaning the condition and its medical routines become a backdrop to childhood itself rather than something new to adjust to.
- Carrying a diagnosis that is mostly invisible Children with MEN1 or MEN2A who have not yet developed clinical symptoms often look and feel completely healthy, which can make it hard for them, their families, and even their schools to know how much the condition should matter day to day.
- Living with MEN2B's distinct physical burden Unlike MEN1 and MEN2A, MEN2B is associated with chronic pain and gastrointestinal symptoms that can directly interfere with daily functioning and mood, not just with long-term cancer risk.
- Navigating a family where risk is shared unevenly Because MEN is autosomal dominant, siblings, parents, and children may or may not carry the same mutation, which can create complicated dynamics around who is screened, who worries, and who feels guilty.
- Thinking ahead to your own children Carriers who are old enough to consider having children of their own must weigh a 50% chance of passing on the mutation, often while still processing their own relationship to the diagnosis.
The psychological toll in adulthood
A study of 43 adults with long-standing MEN2 (average follow-up over a decade) published in Thyroid found that clinically significant anxiety symptoms were present in 42% of patients and depressive symptoms in 26%, measured using the Hospital Anxiety and Depression Scale. Feelings of guilt were reported by 35% of patients who had a mutation-positive child, and these parents also scored higher on measures of discouragement and anxious preoccupation than those without an affected child. Patients who described themselves as well-informed about their disease had significantly lower anxiety and depression scores and higher emotional and cognitive functioning than those who felt less informed (p < 0.05), pointing to patient education as a concrete, modifiable lever for psychological wellbeing.
Why surveillance itself is psychologically complicated
A qualitative study of 12 patients with MEN1, MEN2A, or MEN2B published in the Journal of Genetic Counseling found that lifelong tumor screening is experienced as fundamentally ambiguous rather than simply reassuring or simply stressful. Participants described screening as something that brings the condition "to the foreground" of daily life and can intensify uncertainty, while also providing a sense of control that allows it to "fade into the background" between appointments. This same ambivalence may help explain one of the most striking findings from the 2026 Dutch pediatric study: parents' proxy reports of their child's quality of life were significantly higher — more optimistic — than children's own self-reports on every domain except one: emotional functioning. In other words, parents may track their child's physical symptoms, school performance, and social life reasonably well, but a child's inner emotional experience of living with MEN may not be something a parent can reliably observe from the outside. It has to be asked about directly.
What can help
- Ask directly about feelings, not just symptoms Because parents tend to rate their child's quality of life as better than the child rates it themselves in every area except emotional functioning, regular, direct conversations about how your child feels — not just how they are doing physically — are especially valuable.
- Treat pain as a mental health issue too, especially in MEN2B If chronic pain or gastrointestinal symptoms are part of your or your child's experience, know that these physical burdens are closely tied to mood, and that treating them is also a way of protecting mental health.
- Name the guilt if it's there Guilt about passing on a mutation to a child is common, reported by over a third of parents with an affected child in one study. Naming it with a therapist, genetic counselor, or support group can loosen its grip.
- Ask your care team to explain, not just screen Patients who felt well-informed about their condition had measurably better anxiety, depression, and functioning scores. Understanding what each test is for and what the results mean is itself a form of psychological support.
- Find other families living with MEN Because the condition is rare and experienced differently depending on which type you carry, connecting with other MEN families through a genetic counselor or patient organization can reduce the isolation that comes with an uncommon diagnosis.